AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16087660
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture (Vamin 18 g N/l)
Trial: 1725539
Drug: Diltiazem (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (sustained-release or conventional tablets)
Trial: 1725539
Drug: Diltiazem and
RxNorm normalized name: Diltiazem and enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem and captopril (combination therapy)
Trial: 1725539
Drug: Diltiazem with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem with hydrochlorothiazide or atenolol (combination therapy)
Trial: 1725539
Drug: Diltiazem (monotherapy)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (monotherapy)
Trial: 31567875
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) topic
Trial: 31567875
Drug: Self-administered learning
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered learning modules
Trial: 29167052
Drug: Exposure-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive behavior therapy (CBT) for SHA, 12 weeks
Trial: 25749132
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) program, 6-week duration, 6 lessons using a Manga story
Trial: 23727057
Drug: Microdose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdose of (14)C‐tolbutamide (100 μg)
Trial: 19222929
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of antimicrobial therapy (2 weeks intravenous ceftriaxone and 2 weeks oral ciprofloxacin)
Trial: 19222929
Drug: Chloramphenicol or
RxNorm normalized name: chloramphenicol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol or ceftriaxone treatment (duration not specified)
Trial: 12742869
Drug: Present-centered comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-centered comparison treatment
Trial: 12742869
Drug: Trauma-focused group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused group therapy (adequate dose)
Trial: 8866262
Drug: Bonding agent
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonding agent and light‐cured composite resin
Trial: 8866262
Drug: Conventional glass‐ionomer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glass‐ionomer, bonding agent and light‐cured composite resin
Trial: 8866262
Drug: Light‐cured glass‐ionomer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light‐cured glass‐ionomer, extended 0.3 mm short of the enamel margin, bonding agent and light‐cured composite resin
Trial: 8866262
Drug: Light‐cured glass‐ionomer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light‐cured glass‐ionomer, extended 1 mm short of the enamel margin, bonding agent and light‐cured composite resin
Trial: 26930607
Drug: GSK1070806 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 0.25 mg/kg
Trial: 26930607
Drug: GSK1070806 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1070806 5 mg/kg
Trial: 24456510
Drug: Weekly monetary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly monetary incentives for fitness-center attendance during fall semester
Trial: 22198821
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera leaf gel (300 mg capsule every 12 hours for 2 months)
Trial: 20954664
Drug: Viscoseal (hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoseal (hyaluronic acid) injection
Trial: 18203570
Drug: INSIGHT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INSIGHT therapy
Trial: 16355440
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of rhubarb extract (50 mg.kg(‐1))
Trial: 16355440
Drug: Retention enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retention enema administration of rhubarb extract (50 mg.kg(‐1))
Trial: 16355440
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and retention enema administration of rhubarb extract
Trial: 11867397
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine (25 mg in 8.3% glucose)
Trial: 11867397
Drug: Plain ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain ropivacaine (25 mg)
Trial: 7474676
Drug: Naloxone 0.1
RxNorm normalized name: naloxone 0.18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.1 mg/kg i.v. bolus, followed by 0.1 mg/kg/hr
Trial: 7474676
Drug: HOI during
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HOI during concomitant naloxone administration
Trial: 28137634
Drug: Metoclopramide administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide administration in patients with NLR greater than 2 (group II)
Trial: 28137634
Drug: Metoclopramide administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide administration in patients with NLR less than 2 (group I)
Trial: 24026159
Drug: Chiropractic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic therapy
Trial: 19708000
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg
Trial: 11710710
Drug: diacerein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein (50 mg twice a day)
Trial: 8331204
Drug: Vigabatrin single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin single oral doses (0.5 to 4.0 g)
Trial: 8331204
Drug: Vigabatrin multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin multiple oral doses (0.5 to 2.0 g every 12 hours)
Trial: 29751001
Drug: Ixekizumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (160 mg starting dose followed by 80 mg every 2 weeks, then 80 mg every 4 weeks during extension)
Trial: 24122840
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with atenolol and HCTZ
Trial: 20879647
Drug: Standard reverse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard reverse L-flap (RLF)
Trial: 12093440
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition or fiber‐free enteral nutrition (group A)
Trial: 8787257
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthetic (propofol for induction followed by propofol infusion)
Trial: 8787257
Drug: Combined intravenous‐inhalational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous‐inhalational anaesthetic (propofol with isoflurane in oxygen‐enriched air)
Trial: 2025840
Drug: Local irradiation
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local irradiation only (L‐XRT)
Trial: 2025840
Drug: Local radiation
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local radiation doses over 4500 cGy
Trial: 2025840
Drug: Local radiation
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local radiation doses less than 4500 cGy
Trial: 6465150
Drug: Decentralized unit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decentralized unit dose system (control)
Trial: 24813374
Drug: Long-acting dexmethylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting dexmethylphenidate (D-MPH) at doses of 10-20 mg
Trial: 24813374
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts (MAS) at doses of 10-20 mg
Trial: 23123106
Drug: AH-adjuvanted PcpA
RxNorm normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH-adjuvanted PcpA (25 μg)
Trial: 23123106
Drug: AH-adjuvanted PhtD-PcpA
RxNorm normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH-adjuvanted PhtD-PcpA (10, 25, or 50 μg each)
Trial: 23123106
Drug: Unadjuvanted PhtD-PcpA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unadjuvanted PhtD-PcpA (25 μg each)
Trial: 23123106
Drug: AH-adjuvanted vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH-adjuvanted vaccines
Trial: 19195328
Drug: lamivudine plus
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine plus pegylated interferon‐alpha2b combination therapy for 24 weeks
Trial: 19195328
Drug: lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine monotherapy for 28 weeks
Trial: 15787659
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mixture plus metformin
Trial: 20649032
Drug: Glargine plus
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine plus metformin
Trial: 12453070
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg IVIG
Trial: 12453070
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg IVIG
Trial: 2248072
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 to 328 mg in first study; 294-408 mg in second study)
Trial: 2248072
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 to 96 mg in first study; 95-129 mg in second study)
Trial: 7364977
Drug: Corticosteroid antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid antimicrobial cream with fluocinonide 0.05%
Trial: 7364977
Drug: Corticosteroid antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid antimicrobial cream with triamcinolone 0.1%
Trial: 7364977
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing only antimicrobial agents
Trial: 31835476
Drug: Fibre-enriched orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibre-enriched orange juice (1.4 g/100 mL of citrus fibre)
Trial: 26163858
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education with exercise therapy
Trial: 26163858
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education without exercise therapy
Trial: 3294615
Drug: Cefamandole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (15 mg/kg)
Trial: 3294615
Drug: Tobramycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1.5 mg/kg)
Trial: 3294615
Drug: Tobramycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (3 mg/kg)
Trial: 3294615
Drug: Cefamandole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (15 mg/kg) + Tobramycin (1.5 mg/kg)
Trial: 3294615
Drug: Cefamandole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (15 mg/kg) + Tobramycin (3 mg/kg)
Trial: 30431426
Drug: FS Spiromax
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS Spiromax 500/50 µg
Trial: 30431426
Drug: Seretide Accuhaler
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seretide Accuhaler 50/500 µg
Trial: 30431426
Drug: FS Spiromax
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS Spiromax 500/50 µg with charcoal block
Trial: 30431426
Drug: Seretide Accuhaler
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seretide Accuhaler 50/500 µg with charcoal block
Trial: 14699543
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intravenous antibiotics)
Trial: 11721154
Drug: Standard calcium
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard calcium reduced diet (300 mg/24 h) for 4 weeks after a 3-week run-in period (dietary calcium content 700-1,000 mg/24 h)
Trial: 9012545
Drug: Sizofiran (SPG)
RxNorm normalized name: Sizofiran
DrugBank: Sizofiran (DB13128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sizofiran (SPG) administration
Trial: 3891497
Drug: Heidelberg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heidelberg capsule after a 4-ml/kg liquid fatty meal
Trial: 3891497
Drug: Liquid meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid meal (200 ml of diluted light cream)
Trial: 27421057
Drug: Combination HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination HIV prevention package (including household‐based HIV counselling and testing and anti‐retroviral treatment eligibility regardless of CD4‐count)
Trial: 24645793
Drug: Avenanthramide (AVA)
RxNorm normalized name: AVENANTHRAMIDES
DrugBank: Avenanthramides (DB14743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenanthramide (AVA) supplementation (9.2 mg AVA per day)
Trial: 23235391
Drug: Low-dose erythropoietin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose erythropoietin stimulating agent (ESA) treatment
Trial: 23235391
Drug: No erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No erythropoietin stimulating agent (no-ESA) treatment
Trial: 19896252
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100ml of a fermented milk product
Trial: 12435170
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U weekly (increased to 60,000 U weekly for inadequate response)
Trial: 30156436
Drug: MEC (DigeZyme®)
RxNorm normalized name: CATHETER,EXTERNAL MALE QIVI MEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEC (DigeZyme®) 50 mg, TID for 60 days
Trial: 19717722
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily from days 1 to 5 with 100 mg lamotrigine on day 4
Trial: 19717722
Drug: Lamotrigine 100
RxNorm normalized name: lamotrigine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 100 mg alone on day 32
Trial: 11497195
Drug: Omapatrilat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (10 or 20 mg, titrated to 20 or 40 mg) plus 25 mg of HCTZ
Trial: 11497195
Drug: Omapatrilat (20/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (20/40 mg) plus 25 mg of HCTZ
Trial: 11497195
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 25 mg of HCTZ
Trial: 2938394
Drug: Alfentanil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (50 micrograms/kg) and atracurium (0.5 mg/kg)
Trial: 2938394
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 micrograms/kg) and pancuronium (0.07 mg/kg)
Trial: 27831635
Drug: Short GnRH
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short GnRH agonist protocol
Trial: 27831635
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate plus FSH and antagonist
Trial: 25335325
Drug: Jiangtang Xiaozhi
RxNorm normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangtang Xiaozhi Capsule (JTXZC), 4 pills three times per day for 8 weeks
Trial: 25335325
Drug: Pioglitazone Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone Tablet, 15 mg once daily for 8 weeks
Trial: 18199700
Drug: Presumptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumptive treatment
Trial: 15928281
Drug: Complicated grief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complicated grief treatment
Trial: 12869086
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (n=45)
Trial: 8931917
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 mg, intravenously)
Trial: 26905703
Drug: Esmolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 50 mg
Trial: 7008800
Drug: levamisole 150
RxNorm normalized name: levamisole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole 150 mg weekly
Trial: 28270226
Drug: Adipose-derived mesenchymal
RxNorm normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived mesenchymal stem cells (ASC) administered to the submandibular glands
Trial: 28270226
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to the submandibular glands
Trial: 26451726
Drug: Both supplement
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both supplement groups
Trial: 19207345
Drug: computer-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: computer-based treatment
Trial: 17987226
Drug: HPV L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV L1 VLP vaccines
Trial: 12772885
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, plus a 5‐day continuous infusion of 750 mg/m2 5‐fluorouracil (FU; TCF)
Trial: 12772885
Drug: docetaxel 85
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 85 mg/m2 plus cisplatin 75 mg/m2 (TC)
Trial: 9850487
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment policy with sulfonylurea
Trial: 9850487
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment policy with metformin
Trial: 9850487
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment policy with insulin
Trial: 9850487
Drug: Conventional policy
RxNorm normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional policy (diet therapy)
Trial: 338105
Drug: Fluorouracil, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil, 1 g daily, as a continuous infusion into the portal venous system during the first seven days after operation.
Trial: 26218029
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed prostheses
Trial: 21524765
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 160 mg/bid for 8 weeks
Trial: 18056769
Drug: Cyclical oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical oral contraception (21‐d active/7‐d placebo for six consecutive 28‐d cycles)
Trial: 18056769
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraception (168‐d active pill)
Trial: 12698777
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration (2L of water daily)
Trial: 11200750
Drug: Immunochromatographic assay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochromatographic assay detecting IgG antibodies against antigen 38 kDa (Rapid Test TB)
Trial: 1281729
Drug: Terazosin (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (2, 5 or 10 mg)
Trial: 6373442
Drug: Piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide 6 mg b.i.d.